The combination targets two distinct steps in nucleic acid metabolism which can be synergistic in some contexts and may reduce the emergence of resistance because dual mutations are less likely, but clinicians must consider additive toxicity and drug interactions, particularly rifampin's induction of hepatic enzymes that lowers levels of co-administered drugs.